[Osteoporosis treatment with biphosphonates: Approaches to care reality].
OBJECTIVE
Osteoporosis predominantly affects menopausal women and has a significant morbidity expressed as fractures. The study aimed to describe the types of bisphosphonates used to treat osteoporosis in post-menopausal women and to establish how treatment non-compliance affects the fracture rate.


METHODS
Retrospective cohort study of women on active treatment with bisphosphonates for the past five years.


METHODS
Utebo Health Centre (Zaragoza) (16,000 inhabitants) with a general medical quota of 1,890 patients).


METHODS
A total of 129 women who were on active treatment with bisphosphonates for five years were included.


METHODS
The distribution by drug was analysed, as well as the percentage of women who did not comply with the treatment correctly and any identified fractures.


RESULTS
A total of 129 women on treatment were identified (13.0% of all women patients): alendronic acid (45.7%), ibandronic acid (21.7%), risedronic acid (19.4%) and alendronic acid plus cholecalciferol (13,2%). 19.4% of women stopped their treatment after at least 3 months. Thirteen hip fractures were identified.


CONCLUSIONS
The overall treatment compliance was 80.6%, Depending on the type of bisphosphonate: alendronic acid plus cholecalciferol (88.2%), risedronic acid (88.0%), alendronic acid (78.0%), ibandronic acid (75.0%). The incidence of hip fractures was similar incidence to that observed with respect to non-compliance to treatment. Lack of therapeutic compliance is common in menopausal women, and measures should be promoted to increase effectiveness as well as to make patients aware of the importance of continuing treatment.
Vicente Molinero
Angel
A
Urgencias, Hospital Royo Villanova, Zaragoza, España.
Lou Arnal
Salvador
S
Medina Orgaz
Esteban
E
Muñoz Jacobo
Sergio
S
Antonio Ibáñez Estrella
José
J
D015331:Cohort Studies; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008593:Menopause; D010024:Osteoporosis / Q000188:drug therapy*; D058866:Osteoporotic Fractures / Q000517:prevention & control; D012189:Retrospective Studies; D016903:Drug Monitoring
D004164:Diphosphonates